A technology appraisal will assess ‘the clinical and cost effectiveness of botulinum toxin type A within its licensed indication for the prophylaxis of headaches associated with chronic migraine’.
After botulinum toxin was licensed for treating chronic migraine, RCGP headache champion Dr David Kernick warned in GP that practical and funding issues would initially limit availability of the treatment. However, if botulinum toxin type A is accepted for the treatment of migraine by NICE, NHS services will have a legal duty to provide access to it.
Other treatments to be assessed by NICE include lenalidomide for multiple myeloma and myelodysplastic syndromes and erlotinib for lung cancer. Treatments are referred to NICE for appraisal by ministers. The topics selected by ministers have undergone a consultation process on the remit and scope of the appraisals NICE should undertake.